Regulatory ApprovalChemomab announced positive feedback from the FDA following its End-of-Phase 2 and Type C meetings to support advancing nebokitug into Phase 3 development for primary sclerosing cholangitis.
Strategic PartnershipsChemomab is in active strategic partnering discussions to advance the program into Phase 3, which is expected to bring the asset forward significantly.
Study DesignNebokitug's single pivotal Phase 3 study is expected to not require a liver biopsy, using a clinical events-based endpoint, making it less costly and easier to enroll.